Oncology startup Volastra Therapeutics inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced the New York-based company’s seed funding round was extended from $12 million to $44 million.
Merck’s Keytruda Approved for First-Line Treatment of Colorectal Cancer
Approvals, Blockbusters, Checkpoint Inhibitors, Clinical Data, FDA, FDA/Regulatory, Microsatellite instability-high (MSI-H) cancer, Microsatellite Instability-High (MSI-H) Colorectal Cancer, Mismatch Repair Deficient (dMMR) Colorectal Cancer, Monotherapy, New Indications, PD-1/PD-L1 inhibitors, Progression-Free Survival (PFS), TherapeuticsThe U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.